Introduction: Inflammatory response plays a key role in coronavirus disease 2019 (COVID-19) as it has been shown that the resulting cytokine storm increases its severity.

Objectives: To investigate the role of procalcitonin (PCT) as a predictor of in-hospital mortality in patients with severe to critical COVID-19.

Patients and Methods: In a retrospective cohort study, 150 patients with severe to critical COVID-19 consecutively admitted to the intensive care unit (ICU) were investigated. Patients’ demographics, clinical and laboratory findings, and PCT level were collected upon their admission to the hospital and from the disease outcome data.

Results: Of the 150 patients who entered the study, 77 were discharged alive from the hospital. The mean age of the patients was 60.9 ±16.3 years and 51.3% of them were male. The mean PCT level was significantly higher in the deceased patients than in survivors (2.4 ± 3.4 versus 0.7 ± 1.3, \( P < 0.005 \)). The logistic regression analysis indicated that PCT, creatinine and urea levels were independently associated with in-hospital mortality.

Conclusion: Serum PCT levels are associated with in-hospital mortality in COVID-19 patients admitted to ICU and could be used as a simple tool to predict adverse outcomes and expedite timely and appropriate interventions.

Keywords: COVID-19, Procalcitonin, Outcome, Mortality, Severity

Please cite this paper as: Zakeri A, Faraone A, Matin S. Does procalcitonin play a role as a predictor of in-hospital mortality among COVID-19 patients admitted to intensive care unit? J Parathyroid Dis. 2022;10:e9144. doi:10.34172/jpd.2022.9144.

Copyright © 2022 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Implication for health policy/practice/research/medical education**

High serum procalcitonin level is significantly associated with adverse outcome in COVID-19 patients and can be used as a predictor of mortality.

Support, use of antibiotics, and disease outcomes were all collected from electronic medical records.

**Statistical analysis**

For statistical analyses, SPSS version 19 was employed. The significance level for all of the tests was set at 0.05 and all of the results were reported in the form of the mean values ± standard deviation. To compare different variables, the statistical tests of Mann-Whitney U and chi-square were used. Additionally, t test and regression tests were conducted too. The prognostic value of PCT was assessed by receiver-operating characteristic analysis. Moreover, Youden index was calculated to obtain the optimal threshold value. In order to determine those factors that predict in-hospital mortality, a logistic regression analysis by was conducted.

**Results**

Among the 150 patients suffering from severe COVID-19 who entered the study, 77 cases were discharged alive from the hospital and 73 cases died. The mean age was 60.9 ± 16.3 (age range 21-93 years), and 51.3% were male. 68% of the patients were intubated, 57.3% suffered from severe hemodynamic disorder, and 42% had fever. The most prevalent background disease was diabetes (18%). The mean length of hospital stay was 18 ± 11.8 days. Among the deceased patients, death occurred on average 15.5 ± 10.6 days after ICU admission. Around 20.5% of the patients who died had diabetes and 10.9% of them suffered from chronic renal failure. The study population was divided into 2 groups based on the disease outcome (survivors versus non-survivors). Patient demographics, comorbidities and length of hospital stay (Table 1) and laboratory results (Table 2) are presented separately for each group.

The area under the ROC curve for PCT was 0.727 (Figure 1, Table 3). Based on this figure, the optimum cut-off point for PCT as a predictor of in-hospital death was determined to be 0.12, with a sensitivity of 90% and a specificity of 68%.

The PCT level in the deceased patients was significantly higher than that of the survivors (2.43±3.40 versus 0.73±1.28). In order to determine the relationship between serum PCT and in-hospital death, binary logistic regression was used, the results of which are summarized in Table 4. The logistic regression analysis indicated that PCT, creatinine and urea levels were independently associated with in-hospital mortality. More specifically, an increase of 1 unit in PCT level led to an increase of 0.66% in the mortality risk of COVID-19 patients (OR=0.668; 95% CI: 0.518-0.862). Additionally, an increase of one unit in creatinine and urea level led to an increase of respectively 1.25% and 0.98% in the mortality risk of COVID-19 patients.

**Discussion**

The aim of this study was to explore the role of PCT as a predictor of adverse outcome in a cohort of patients affected by severe to critical COVID-19. For this purpose, 150 COVID-19 patients hospitalized in ICU were investigated. The results showed that serum PCT level in the deceased patients was significantly higher than that of the survivors. The logistic regression model confirmed the positive correlation between PCT and mortality, meaning that as serum PCT level increases, mortality also increases.

| Variables                  | All patients (n = 150) | Survivors (n = 77) | Non-survivors (n = 73) |
|----------------------------|-----------------------|--------------------|------------------------|
| Age (y)                    | 60.92 ± 16.33         | 55.47 ± 16.35      | 66.51 ± 14.40          |
| Gender                     |                       |                    |                        |
| Male                       | 77                    | 44                 | 33                     |
| Female                     | 73                    | 32                 | 41                     |
| Hospitalization time (9)   | 18.01 ± 11.87         | 18.99 ± 11.26      | 17.03 ± 12.57          |
| Underlying disease, n (%)  |                       |                    |                        |
| Hypertension               | 16(10.6)              | 10(12.9)           | 6(8.2)                 |
| Chronic kidney disease     | 13(8.6)               | 5(6.4)             | 8(10.9)                |
| Diabetes mellitus          | 27(18)                | 12(15.5)           | 15(20.5)               |
| Coronary artery disease    | 10(6.6)               | 7(9)               | 3(4.1)                 |
| Cancer                     | 3(2)                  | 1(0.6)             | 2(1.2)                 |
| Endotracheal intubation, n (%) | 105 (70)          | 32 (41.6)          | 73 (100)               |
| Hemodyamic instability, n (%) | 86 (57.3)         | 26 (34.2)          | 60 (81.1)              |
| Fever, n (%)               | 63 (48)               | 21 (16)            | 42 (81.1)              |
Our results are consistent with earlier works. The meta-analysis by Lippi et al found that increased serum PCT levels were associated with a nearly 5-fold higher risk of severe disease in patients affected by COVID-19. Moreover, the authors suggested that periodic assessment of the PCT level might be helpful in predicting the evolution of COVID-19 towards a more severe form (8). Vazzana et al found that increased PCT levels were more prevalent in patients with severe COVID-19 than in those with non-severe course (22.8% versus 5.8%) (OR, 5.92; 95% CI, 3.20 to 10.94), and patients with higher than normal PCT levels were more likely to have a poor outcome (44.0% versus 11.3%) (OR, 13.1; 95% CI, 7.37 to 23.1) (10). In another study, Hu et al investigated serum PCT in COVID-19 patients and found that it had increased in the deceased cases as their condition had become more severe. Therefore, the increase of serum PCT level can be a warning sign for severe forms of COVID-19 (11).

Procalcitonin is a glycoprotein with no hormonal activity, precursor of the hormone calcitonin (12). The serum PCT level in healthy people is lower than detectable, but its level increases as the result of systemic inflammations, especially during bacterial infections (7). In the presence of bacterial infection, the synthesis and release of PCT into the blood from sources other than thyroid increase considerably and actively continue with the increase of interleukin-1beta (IL-1β), tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) concentrations (8). However, the synthesis of this biomarker is prohibited by interferon gamma (IFN-γ), whose concentration increases during viral infections (13). Therefore, PCT level is relatively lower in viral infections, which can be used to distinguish between bacterial and viral infections (14). In addition to serious bacterial infections, elevated PCT values can be found in critically-ill patients at increased risk of organ injury (15). In the present study, the mean PCT value in the enrolled severe to critically-ill patients was higher than normal. In line with this finding, Liu et al reported significantly higher levels of IL-6, C-reactive protein (CRP), and PCT in patients with severe COVID-19 than in those with milder forms, and showed that inflammatory factors play a key role in the progression of the disease from mild to severe forms (16).

### Table 2. Laboratory findings of patients in separate groups

| Variables         | All patients (n = 150) | Survivors (n = 77) | Non-survivors (n = 73) | P value |
|-------------------|------------------------|--------------------|------------------------|---------|
| White blood cells (10⁹/L) | 8314.57 ± 3221.10      | 7404.73 ± 4371.268 | 8055.21 ± 4018.957     | 0.45    |
| Procalcitonin (ng/mL)    | 1.57 ± 2.69            | 0.73 ± 1.28        | 2.43 ± 3.40            | 0.001*  |
| Platelets (10⁹/L)         | 149040.28 ± 121002.44   | 161199.45 ± 130695.27 | 136552.49 ± 109623.43  | 0.27    |
| NLR                     | 8.51 ± 9.10            | 7.08 ± 9.53        | 10.02 ± 8.43           | 0.048   |
| Hb (g/dL)               | 12.99 ± 2.49           | 13.11 ± 2.37       | 12.86 ± 2.61           | 0.56    |
| Urea (mg/dL)            | 53.17 ± 40.29          | 42.11 ± 28.60      | 64.54 ± 47.06          | 0.000*  |
| Cr (mg/dL)              | 1.44 ± 1.27            | 1.32 ± 1.41        | 1.56 ± 1.08            | 0.002*  |
| Mg (mg/dL)              | 2.07 ± 0.57            | 2.04 ± 0.55        | 2.09 ± 0.59            | 0.26    |
| Na (mg/dL)              | 138.87 ± 6.31          | 138.97 ± 5.79      | 138.77 ± 6.83          | 0.84    |
| K (mg/dL)               | 4.28 ± 0.90            | 4.27 ± 1.10        | 4.29 ± 0.65            | 0.13    |
| Ca (mg/dL)              | 8.25 ± 0.78            | 8.34 ± 0.83        | 8.16 ± 0.72            | 0.16    |
| P (mg/dL)               | 3.65 ± 1.35            | 3.49 ± 0.80        | 3.81 ± 1.74            | 0.77    |

Abbreviations: NLR, Neutrophil to lymphocyte ratio; Hb, hemoglobin; Cr, creatinine; Mg, magnesium; Na, sodium; K, potassium; Ca, calcium; P, phosphorus.

Notes: *P < 0.05 in independent samples t test between two groups versus baseline. The data are presented as mean ± SD.

### Table 3. Area under the curve

| Test Result Variable(s) | Procalcitonin |
|-------------------------|--------------|
| Area                    | 0.727        |
| Std. Error              | 0.041        |
| Asymptotic Sig           | 0.000        |
| Asymptotic 95% CI        | 0.717 - 1.03 |

### Table 4. Binary logistic regression result

| Variable    | P value | Exp(B) |
|-------------|---------|--------|
| Procalcitonin | 0.002   | 0.668  |
| Urea        | 0.018   | 0.983  |
| Cr          | 0.026   | 1.00   |

Figure 1. ROC curve.
One potential reason for the higher serum PCT levels in patients with severe to critical COVID-19 might be the presence of a superimposed bacterial co-infection. According to previous studies, secondary bacterial infections in critically-ill COVID-19 patients occurred between 14 and 28% of case (17-19). Huang et al observed in their study that 4 of 41 patients, the patients hospitalized in ICU were afflicted with secondary infection, 3 of which had serum PCT levels higher than 0.5 ng/mL (20). They also showed that the increase in the level of this biomarker can be indicative of a poor prognosis.

Vanhomwegen et al assessed the values of PCT at admission to ICU in 66 critically-ill COVID-19 patients. They found a total of 7 (11%) patients who were co-infected with bacterial pathogen upon ICU admission. Median PCT levels were not significantly different in patients with (11.8 ng/mL; IQR 0.3–90.3) or without (0.7 ng/mL; IQR 0.3–2.8) co-infection (P = 0.14). The authors concluded that PCT is not reliable to diagnose bacterial co-infection in COVID-19 patients within 48 hours of admission (21).

In the present study, the presence of secondary bacterial infection was not assessed, and we were unable to explore the relationship between this complication and PCT levels in severe to critically-ill COVID-19 patients. To date, it remains unclear whether PCT levels in deteriorating COVID-19 patients are increased because of bacterial infections or hyperinflammatory state (cytokine storm) with target organ injury. As a consequence, it is still undefined if PCT may be used for detecting superimposed bacterial infections and guiding antibiotic therapy in COVID-19 patients (10).

**Conclusion**

Serum PCT levels were significantly associated with mortality in a cohort of COVID-19 patients admitted to ICU. Consequently, the PCT level could be used to early identify those patients at increased risk of complications and poor outcome who may benefit from timely and more intensive care management. Further investigation is needed to support this conclusion.

**Limitations of the study**

Limitations of the study are small number of patients, retrospective and monocentric design, which might limit its generalization.

**Acknowledgements**

We hereby sincerely thank all of the patients who participated in this study as well as all of the people who cooperated in conducting this research.

**Authors’ contribution**

Conceptualization: AZ and SM. Methodology: AZ and SM. Investigation: AZ, SM and AF. Resources: AZ, SM and AF. Data Curation: AZ, SM and AF. Writing—Original Draft Preparation: AZ, SM and AF. Writing—Review and Editing: AZ, SM and AF. Supervision: AZ, SM and AF. Project Administration: AZ, SM and AF.

**Data availability statement**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Conflicts of interest**

The authors declare that they have no conflicts of interest.

**Ethical issues**

The research followed the tenets of the Declaration of Helsinki. The institutional ethical committee at Ardabil university of medical sciences approved all study protocols (IR.ARUMS.REC.1399.088). The authors have entirely observed ethical issues (including plagiarism, data fabrication, and double publication).

**Funding/Support**

This study was funded by the vice-chancellery for research at Ardabil university of medical sciences as a research project.

**References**

1. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1-9. doi: 10.12932/AP-200220-0772.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3.
3. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39:206-17. doi: 10.1086/421997.
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600-7. doi: 10.1016/S0140-6736(04)15591-8.
5. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84-93. doi: 10.1164/rccm.200512-1922OC.
6. Christ-Crain M, Müller B. Procalcitonin in bacterial infections: hype, hope, more or less? Swiss Med Wkly. 2005;135:451-60.
7. Flóraiczyk B. Structure and diagnostic value of procalcitonin. Ann Univ Mariae Curie Skłodowska Med. 2003;58:338-42.
8. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-1. doi: 10.1016/j.cca.2020.03.004.
9. Riaz H. Large liver abscess: unusual presentation of fascioliasis: case report and literature review. Saudi J Gastroenterol. 2001;7:113-5.
10. Vazzana N, Dipaola F, Ognibene S. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. Acta Clin Belg. 2022;77:268-272. doi: 10.1080/17843286.2020.1824749.
11. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56:106051. doi: 10.1016/j.ijantimicag.2020.106051.
12. Choi JJ, McCarthy MW. Novel applications for serum procalcitonin testing in clinical practice. Expert Rev Mol Diagn. 2018;18:27-34. doi: 10.1080/14737159.2018.1407244.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. doi:
10.1136/bmj.327.7414.557.
14. Rodríguez A, Reyes LF, Monclou J, Suberviola B, Bodí M, Sirgo G, et al. Relationship between acute kidney injury and serum procalcitonin (PCT) concentration in critically ill patients with influenza infection. Med Intensiva (Engl Ed). 2018;42:399-408. doi: 10.1016/j.medint.2017.12.004.
15. AlRawahi AN, AlHinai FA, Doig CJ, Ball CG, Dixon E, Xiao Z, et al. The prognostic value of serum procalcitonin measurements in critically injured patients: a systematic review. Crit Care. 2019;23:390. doi: 10.1186/s13054-019-2669-1.
16. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370.
17. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-9. doi: 10.1016/j.cmi.2020.07.016.
18. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Med. 2020;46:2071-4. doi: 10.1007/s00134-020-06219-8.
19. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10:119. doi: 10.1186/s13613-020-00736-x.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
21. Vanhomaegem C, Veliziots I, Malinverni S, Konopnicki D, Dechamps P, Claus M, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. Ir J Med Sci. 2021;190:1649-1652. doi: 10.1007/s11845-020-02485-z.